Ride New York. Ride for ALS.

Ride all five boroughs of New York City with Team Target ALS at the 2026 TD Five Boro Bike Tour on May 3.

Apply to Ride With Team Target ALS

Ride with purpose in one of the world’s most iconic bike tours

Target ALS has been selected as an official charity partner for the 2026 TD Five Boro Bike Tour, the world’s largest one-day charity bike ride. This iconic, traffic-free 40-mile ride takes cyclists through all five boroughs of New York City, across bridges and roadways normally closed to bikes, and brings together more than 32,000 riders from around the world. On Sunday, May 3, 2026, you can ride as part of Team Target ALS and help accelerate research to end ALS.

Why ride with Target ALS

By riding with Team Target ALS, you’re doing more than taking on an unforgettable challenge. You’re directly supporting an ecosystem designed to break down barriers and accelerate ALS research.

Funds raised through the TD Five Boro Bike Tour support Target ALS’s mission to accelerate ALS research, fuel bold scientific ideas, enable open-access tools and data, and conduct global studies that bring the ALS community closer to effective treatments.


Team Target ALS details


Who we’re looking for

We’re looking for 20 passionate riders who believe in the power of movement, community, and science to create change. You do not need to be a professional cyclist, just committed to training, fundraising, and riding with purpose.

Whether you’re a seasoned rider or taking on your first long-distance tour, if you’re motivated to support ALS research, we want to hear from you.

Ride with Team Target ALS

Apply today

Ride the city. Move research forward.

Bike New York TD Five Boro Bike Tour 2023. Photo by Jacob Slaton / Whatever Media Group, LLC

The TD Five Boro Bike Tour is more than a ride; it’s a celebration of New York, community, and what’s possible when people come together for a cause that matters.

Join Team Target ALS and help drive the research that will change what it means to receive an ALS diagnosis.

Learn more about Target ALS

Our mission